XML 26 R14.htm IDEA: XBRL DOCUMENT v3.26.3
STOCK-BASED COMPENSATION
9 Months Ended
Sep. 30, 2026
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

NOTE 6. STOCK-BASED COMPENSATION

 

In connection with the Closing, the Company adopted the Tevogen Inc. 2024 Omnibus Incentive Plan (the “2024 Plan”) and no longer grants awards pursuant to the 2020 Equity Incentive Plan (the “2020 Plan”). Each restricted stock unit (“RSU”) award granted under the 2020 Plan that was outstanding and unvested as of the Closing Date was automatically canceled and converted into an award under the 2024 Plan with respect to the common stock of the Company (the “Rollover RSUs”). Such Rollover RSUs remain subject to the same terms and conditions as set forth under the applicable award agreement prior to the Closing.

 

In addition to covering the Rollover RSUs, under the 2024 Plan, as of December 31, 2024, the Company was authorized to grant awards up to an aggregate 800,000 shares of common stock. During the year ended December 31, 2025, the number of shares authorized under the 2024 Plan was increased to 977,991. During the nine months ended September 30, 2026, the company was authorized to grant an additional 102 million shares under the 2024 plan. The 2024 Plan provides for the grant of options, stock appreciation rights, restricted common stock (“Restricted Stock”), RSUs, and other equity-based awards. As of September 30, 2026, awards for 90,630,774 shares remained available to be granted under the 2024 Plan.

 

The Company has issued RSUs that are subject to either service-based vesting conditions or service-based and performance-based vesting conditions. Compensation expense for service-based RSUs is recognized on a straight-line basis over the vesting period of the award. Compensation expense for service-based and performance-based RSUs (“Performance-Based RSUs”) is recognized when the performance condition, which is based on a liquidity event condition being satisfied, is deemed probable of achievement. The fair value of RSUs vested during the nine months ended September 30, 2026 and 2025 was $1.7 million and $8.9 million, respectively.

 

On June 27, 2025, the Company issued an aggregate of 185,000 shares of Restricted Stock under the 2024 Plan to the Company’s executive officers, including a grant of 160,000 shares of Restricted Stock to Dr. Saadi. The shares of Restricted Stock granted to Dr. Saadi will vest in four equal annual installments beginning on June 27, 2032 and the shares of Restricted Stock granted to each other grantee will vest in three equal annual installments beginning on June 27, 2030 (the “2025 RSA Vesting Period”), subject in each case to the applicable grantee’s continuous service with the Company through the vesting date, and provided that the shares will automatically vest in full in the event of termination due to death or disability. Pursuant to the terms of these awards, the Company’s executive officers are entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to automatic forfeit. The Company’s executive officers will automatically forfeit all unvested Restricted Stock in the event they depart the Company for any reason, unless termination of their service triggers accelerated vesting pursuant to the terms of the applicable award agreement or the 2024 Plan. The fair value per share for these awards was determined to be $62 per share, equivalent to the Company’s stock price on the grant date, resulting in a total grant date fair value of $11,470,000. In accordance with ASC 718, the Company will recognize compensation expense on a straight-line basis from the grant date until the completion of the 2025 RSA Vesting Period.

 

On July 10, 2026, July 21, 2026 and July 28, 2026, the Company issued an aggregate of 2,245,000 shares of Restricted Stock under the 2024 Plan to the Company’s executive officers and other key employees and consultants, including a grant of 1,220,000 shares of Restricted Stock to Dr. Saadi. The shares of Restricted Stock granted to Dr. Saadi will vest in four equal annual installments beginning on July 10, 2033 and the shares of Restricted Stock granted to each other grantee will vest in three equal installments on the earlier to occur of (i) the first anniversary of the grant date or the Company having achieved aggregate revenue of $50 million since the grant date, (ii) the second anniversary of the grant date or the Company having aggregate revenue of $100 million since the grant date, and (iii) the third anniversary of the grant date or the Company having aggregate revenue of $150 million since the grant date, provided that the grantee remains in service with the Company on the applicable vesting date (the “2026 RSA Vesting Period”), and provided that the shares will automatically vest in full in the event of termination due to death or disability. Pursuant to the terms of these awards, the grantees are entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to automatic forfeit. The grantees will automatically forfeit all unvested Restricted Stock in the event they depart the Company for any reason, unless termination of their service triggers accelerated vesting pursuant to the terms of the applicable award agreement or the 2024 Plan. The fair value per share for these awards was determined to be $5.06, $4.06 and $5.59 per share for grants issued on July 10, 2026, July 21, 2026 and July 28, 2026, respectively, equivalent to the closing price of the Company’s common stock on the grant date, resulting in a total grant date fair value of approximately $11.2 million. The shares granted to Dr. Saadi will vest based on continued service only, and the Company is recognizing their grant-date fair value of approximately $6.2 million on a straight-line basis over the requisite service period ending July 10, 2036.

 

On September 11, 2026, the Company issued an aggregate of 375,000 shares of Restricted Stock under the 2024 plan to the Company’s non-employee directors. The shares of Restricted Stock will vest on three equal annual installments beginning on the anniversary of the grant date. Pursuant to the terms of these awards, the grantees are entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to automatic forfeit. The grantees will automatically forfeit all unvested Restricted Stock in the event they depart the Company for any reason, unless termination of their service triggers accelerated vesting pursuant to the terms of the applicable award agreement or the 2024 Plan. The fair value per share for these awards was determined to be approximately $7.36 per share for grants issued on September 11, 2026, equivalent to the closing price of the Company’s common stock on the grant date, resulting in a total grant date fair value of $2.8 million.

 

On September 14, 2026, the Company issued an aggregate of 8,750,000 shares of Restricted Stock under the 2024 Plan to two of the Company’s executive officers, including a grant of 8,000,000 shares of Restricted Stock to Dr. Saadi. The shares of Restricted Stock will vest if the Company has $1 billion in aggregate revenue by September 30, 2031. Pursuant to the terms of these awards, the Company’s executive officers are entitled to vote the Restricted Stock, but the shares may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to automatic forfeit. The grantees will automatically forfeit all unvested Restricted Stock in the event they depart the Company for any reason. The fair value per share for these awards was determined to be approximately $7.51 per share for grants issued on September 14, 2026, equivalent to the closing price of the Company’s common stock on the grant date, resulting in a total grant date fair value of $65.7 million. As of September 30, 2026, the Company concluded that achievement of the revenue conditions is not probable and has not recognized compensation expense for these awards. If achievement becomes probable, the Company will record a cumulative catch-up for service already rendered and recognize the remainder over the remaining service period.

 

 

Restricted Stock and RSU activity was as follows:

 

   Service-Based Restricted Stock and RSUs 
   Shares  

Weighted average
grant-date fair value

 
Nonvested as of January 1, 2026   619,793   $163.47 
Granted   2,884,000    5.54 
Vested   (201,501)   10.68 
Forfeited   -    - 
Nonvested as of September 30, 2026   3,302,292   $34.86 

 

   Service-Based Restricted Stock and RSUs 
   Shares  

Weighted average
grant-date fair value

 
Nonvested as of January 1, 2025   533,805   $177.00 
Granted   201,997    62.50 
Vested   (114,460)   49.00 
Forfeited   -    - 
Nonvested as of September 30, 2025   621,342   $163.50 

 

   Performance-Based RSUs 
   Shares  

Weighted average
grant-date fair value

 
Nonvested as of January 1, 2026   5,633   $265.67 
Granted   8,750,000    7.51 
Vested   (2,737)   265.67 
Forfeited   -    - 
Nonvested as of September 30, 2026   8,752,896   $7.59 

 

   Performance-Based RSUs 
   Shares   Weighted average
grant-date fair value
 
Nonvested as of January 1, 2025   25,792   $185.00 
Granted   -    - 
Vested   (20,006)   163.50 
Forfeited   -    - 
Nonvested as of September 30, 2025   5,786   $259.00 

 

There was $4,313,292 and $10,090,105 of compensation cost related to shares of service-based Restricted Stock and service-based RSUs during the three and nine months ended September 30, 2026. There was $89,697,722 of unrecognized compensation cost related to shares of service-based Restricted Stock and service-based RSUs as of September 30, 2026, which will be expensed over a weighted average period of 6.3 years. There was $183,363 and $544,767 of compensation cost related to Performance-Based RSUs during the three and nine months ended September 30, 2026. There was $563,675 of unrecognized compensation cost related to Performance-Based RSUs as of September 30, 2026, which will be expensed over a weighted average period of 0.8 years.

 

 

The Company recorded stock-based compensation expense in the following expense categories in the accompanying unaudited consolidated statements of operations:

 

   2026   2025 
   Three months ended September 30, 
   2026   2025 
Research and development  $2,071,924   $2,036,276 
General and administrative   2,424,732    1,208,641 
Total  $4,496,656   $3,244,917 

 

   2026   2025 
   Nine months ended September 30, 
   2026   2025 
Research and development  $6,093,514   $5,583,289 
General and administrative   4,541,358    8,193,662 
Total  $10,634,872   $13,776,951